

PATENT Attorney Docket No. 205733

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Antrim et al.

Application No. 09/614,961

Filed: Jul. 13, 2000

For:

**REDUCED MALTO-OLIGOSACCHARIDES** 

Group Art Unit: 1623 MAY 2 3 2002 Examiner: Unknown

**TECH CENTER 1600/2900** 

RECEIVED

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

 $\bowtie$ within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

In re Appln. of Antrim et al. Application No. 09/614,961 after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes one of: the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below). or the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below). after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance П under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed. Copies of the References  $\boxtimes$ Copies of the references listed on the enclosed Form 1449 are enclosed herewith. Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). A copy of the foreign search report is enclosed herewith.

references were previously furnished are set out below:

The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the

In re Appln. of Antrim et al. Application No. 09/614,961

U.S. APPLICATI	Status (check one)			
U.S. APPLICATIONS	U.S. FILING	PATENTED	PENDING	ABANDONED
	DATE			
1. 09/366,065	8/2/99		X	

## Other Applications

The Examiner's attention is directed to the following U.S. patent application(s)

	U.S. APP	LICATIONS"	S	tatus <i>(check d</i>	one)
	U.S. APPLICATIONS	U.S. FILING DATE	PATENT- ED	PENDING	ABANDON- ED
1.	10/043,365	Jan. 9, 2002		X	
2.	10/023,077	Dec. 13, 2001		X	
3.	09/801,352	Mar. 7, 2001		X	
4.	09/693,496	Oct. 20, 2000		X	
5.	09/693,497	Oct. 20, 2000		X	
6.	09/366/065	Aug. 2, 1999		X	

## Statement under 37 CFR 1.97(e)

	The <b>undersigned</b> hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.	
	The <b>undersigned</b> hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.	
Staten	nent under 37 CFR 1.704(d)	
	The <b>undersigned</b> hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.	
Fees		
	No fee is owed by the applicant(s). The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith.	

In re Appln. of Antrim et al. Application No. 09/614,961

Method of Payment of Fees						
	Attached is a check in the amount of \$. Charge Deposit Account No. 12-1216 in the amount of \$. (A duplicate copy of this communication is enclosed for that purpose.)					
Auth	orization to Charge Additional Fees					
⊠ Instr	If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)  ructions as to Overpayment					
	advious as to overpayment					
	Credit Account No. 12-1216. Refund					
	lu h					
	Allen E. Hoover, Reg. No. 37,354					
	LEYDIG, VOIT & MAYER, LTD.					
	Two Prudential Plaza, Suite 4900					
	180 North Stetson Chicago, Illinois 60601-6780					
	(312) 616-5600 (telephone)					
	(312) 616-5700 (telephone)					
	(5.2) 5.55 (-0.55					